Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Baolin Qu, PhD
Chinese PLA General Hospital
Principal Investigator - Bing Lu, PhD
Cancer Hospital of Guizhou Province
Principal Investigator - Chun Han, PhD
Hebei Medical University Fourth Hospital
Principal Investigator - Conghua Xie, PhD
Zhongnan Hospital
Principal Investigator - Gang Wu, PhD
Tongji Medical College, Huazhong University of Science and Technology, Wuhan Union Hospital
Principal Investigator - Guang Li, PhD
First Hospital of China Medical University
Principal Investigator - Guangying Zhu, PhD
Peking University Cancer Hospital & Institute
Principal Investigator - Jiancheng Li, PhD
Fujian Province Cancer Hospital
Principal Investigator - Jianhua Wang, PhD
Henan Cancer Hospital
Principal Investigator - Jinming Yu, PhD
Shandong Cancer Hospital and Institute
Study Chair - Lvhua Wang, PhD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator - Ming Chen, PhD
Zhejiang Cancer Hospital
Principal Investigator - Qibin Song, PhD
Renmin Hospital of Wuhan University
Principal Investigator - Qin Lin, PhD
The First Affiliated Hospital of Xiamen University
Principal Investigator - Shenglin Ma, PhD
The First People's Hospital of Hangzhou
Principal Investigator - Tingyi Xia, PhD
Chinese PLA General Hospital
Principal Investigator - Yaping Xu, PhD
Zhejiang Cancer Hospital
Principal Investigator - You Lu, PhD
West China Hospital, West China School of Medicine, Sichuan University
Principal Investigator - Zhengfei Zhu, PhD
Fudan University
Principal Investigator - Zhiyong Yuan, PhD
Tianjin Medical University Cancer Institute and Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
- Cancer Institute & Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
- Chinese Pla General Hospital
Beijing, Beijing Municipality, China
- the General Hospital of the People'S Liberation Army
Beijing, Beijing Municipality, China
- Fujian Province Cancer Hospital
Fuzhou, Fujian, China
- the First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
- Guizhou Cancer Hospital
Guiyang, Guizhou, China
- Hebei Medical University Fourth Hospital
Shijiazhuang, Hebei, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- Renmin Hospital of Wuhan University
Wuhan, Hubei, China
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
- the First Hospital of China Medical University
Shenyang, Liaoning, China
- Shandong Cancer Hospital and Institute
Jinan, Shandong, China
- Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
- West China Hospital, West China School of Medicine, Sichuan University
Chengdu, Sichuan, China
- Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
- the First People'S Hospital of Hangzhou
Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Dec 2012
- Primary completion
- 20 Aug 2018
- Completion
- 20 Oct 2018
- Last update posted
- 7 Feb 2017
- Registered enrollment
- 100
- Registry id
- NCT01714908
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.